Write a 1,250 word paper in which you:
Describe the drug approved by the FDA. Include the pharmacodynamics and pharmacokinetic properties of the chosen drug.
Provide an overview of the disease state for which the drug is used.
Describe what is different about this agent compared to currently available therapies.
Discuss the potential risks associated with this agent and any monitoring parameters that are necessary.
Decide whether you would personally prescribe this agent or stick with currently available alternatives.
You are required to cite five to 10 sources to complete this assignment. Sources must be published within the last 5 years and appropriate for the assignment criteria and nursing content.
Prepare this assignment according to the guidelines found in the APA Style Guide, located in the Student Success Center. An abstract is not required.
As indicated in the syllabus, there is an assignment this week. The assignment involves selecting and reviewing a drug that has been FDA-approved during the past year. You may go back to the beginning of 2018 if you wish, giving you more of a selection. Please review the syllabus for instructions on content, and the rubric for this assignment before you start writing your paper. Note that there is a requirement of citing 5 to 10 sources; these are evidence-based clinical sources (no lay public information-if any of your sources are written for the lay public, I will return your paper for rewriting and deduct one letter grade. I am serious about his assignment’s references). As with the previous assignment, use the APA style format for your paper. The assignment calls for a 1000-1250 word submission. Also keep in mind that this does not include the reference section, and the ‘Marsh parameters’ allows you some latitude regarding word count (but do not submit a ‘War & Peace’ size paper). Let’s say a maximum of 1400 words; I am more interested in content, and if it takes a bit more than 1250 words, then so be it.
Ajovy is a drug that was approved on September 14, 2018, by the Food and Drug Administration (FDA) (Donelly & Hodge, 2019). The drug is administered as a prefilled syringe, allowing an individual to self-medicate, or turn to a health provider for the injection to be delivered. Ajovy is meant to be taken every month or every three months, dependent on the instructions that are given by the doctor or health care provider. Ajovy contains a monoclonal antibody called fremanezumab, which is meant to prevent some of the body’s proteins from functioning. It is also made from the body’s immune system cells (Roblee & VanerPluym, 2019). The pharmacodynamics of the Ajovy drug in clinical effects is unknown. The pharmacokinetics of Ajovy is that it reaches the maximum levels of plasma concentrations in about five to seven days after the drug is injected into the individual’s bloodstream. The steady concentrations achieved after constant dosages are seen after about half a year of continuous monthly dosages (Silberstein, Cohen & Yeung, 2019). However, the elimination period of this drug is about 31 days after the individual stops using it.
Ajovy is used to help an individual in the prevention of both the chronic and episodic types of migraine headaches (Roblee & VanerPluym, 2019). Statistic results show that the use of the drug can help reduce the number of migraine days experienced by the individual to about a half. The clinical studies indicated that this was true for both the episodic and chronic types of headaches, which were reduced by over 40%, making the individual’s life easier, hence improving the patient’s quality of life. Episodic migraines are defined as the headaches that may affect an individual about 14 days a month or less, while chronic migraines…